Roles of Androgen Receptor Signaling in Urothelial Carcinoma-Reference-Cited by-同舟云学术

Roles of Androgen Receptor Signaling in Urothelial Carcinoma

Published:2024-02-10 Issue:4 Volume:16 Page:746
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Sundi Debasish¹,Collier Katharine A.²^ORCID,Yang Yuanquan²,Diaz Dayssy Alexandra³^ORCID,Pohar Kamal S.⁴,Singer Eric A.⁴,Gupta Sanjay⁵^ORCID,Carson William E.⁶,Clinton Steven K.⁷,Li Zihai²,Messing Edward M.⁸

Affiliation:

1. Department of Urology, Division of Urologic Oncology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

2. Department of Internal Medicine, Division of Medical Oncology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

3. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

4. Department of Urology, Division of Urologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

5. Department of Urology, Case Western Reserve University School of Medicine, The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA

6. Department of Surgery, Division of Surgical Oncology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

7. Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

8. Departments of Urology, Oncology, and Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA

Abstract

Preclinical and clinical data suggest that androgen receptor signaling strongly contributes to bladder cancer development. The roles of the androgen receptor in bladder carcinogenesis have obvious implications for understanding the strong male sex bias in this disease and for potential therapeutic strategies as well. In this review, we summarize what is known about androgen receptor signaling in urothelial carcinoma as well as in tumor-infiltrating immune cells, reviewing preclinical and clinical data. We also highlight clinical trial efforts in this area.

Funder

U.S. National Cancer Institute

U.S. Department of Defense

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/4/746/pdf

Reference85 articles.

1. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA;Schafer;Eur. Urol.,2023

2. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends;Antoni;Eur. Urol.,2017

3. Socio-economic burden of disease: Survivorship costs for bladder cancer;Michaeli;J. Cancer Policy,2022

4. Sex differences in bladder cancer: Emerging data and call to action;Theodorescu;Nat. Rev. Urol.,2022

5. Unexplained Excess Risk of Bladder Cancer in Men;Hartge;JNCI J. Natl. Cancer Inst.,1990